Instructions for Dimia (ethinylestradiol, drospirenone) tablets
Release Form
The drug is available as a film-coated tablet.
Description Dimia
Tablets are white or almost white, round, biconvex in shape, with "G73" embossed on one side. A white or nearly white nucleus is visible in the cross-section. Packed in blisters of 24 pieces.
ATC Codes ethinylestradiol
The drug belongs to the group G03AA12, which are monophasic oral contraceptives with a combination of estrogen and gestagen.
Clinical and pharmacological group
Combined oral contraceptive.
Active substance Dimia
The composition of the drug includes ethinyl estradiol and drospirenone.
Pharmacotherapeutic group
A contraceptive agent containing estrogen and gestagen.
Shelf life
The drug is good for two years. Do not use after the expiration of the period indicated on the package.
Pharmacological effect Dimia
Dimia® is a combination hormonal contraceptive that has anti-mineralocorticoid and anti-androgenic effects. The contraceptive effect of combination oral contraceptives (COCs) is based on several factors, including suppression of ovulation and changes in the endometrium. Properly applied, the Perl index (number of pregnancies per 100 women per year) is less than 1. However, if pills are missed or not taken, the Perle index may increase.
For women taking COC, menstrual cycles become more regular, painful menstrual periods are reduced, and bleeding intensity and duration decrease, reducing the risk of anemia. COCs with a higher dose of estrogen (50 mcg of ethinyl estradiol) may reduce the risk of endometrial and ovarian cancer, although whether this is a low-dose drug is unknown.
The progestogen drospirenone in Dimia® has a weak antimineralocorticoid effect, preventing weight gain and edema due to estrogen-induced fluid retention. This makes the drug well tolerated. Drospirenone also has a positive effect on premenstrual syndrome (PMS), alleviating symptoms such as psycho-emotional disorders, breast engorgement, headache, muscle and joint pain, weight gain, and other menstrual cycle-related manifestations.
Drospirenone has antiandrogenic activity, contributing to a decrease in symptoms of acne (acne), skin and hair oiliness (seborrhea). Its action is similar to the natural progesterone produced by the body. It is important to note that drospirenone has no androgenic, estrogen, glucocorticoid, or antiglucocorticoid activity.
All these properties, combined with antimeralocorticoid and antiandrogenic activity, make drospirenone similar in biochemical and pharmacological profile to natural progesterone. In combination with ethinyl estradiol, drospirenone also has a beneficial effect on the lipid profile by increasing the plasma concentration of high-density lipoproteins (HDL).
Indications for use Dimia:
Prevent unwanted pregnancy.
Treatment of moderate acne (acne vulgaris)
Relief of symptoms of severe premenstrual syndrome (PMS).
Instructions for use, course duration and dosage Dimia
The drug should be taken daily, at the same time, with a small amount of water. Reception scheme is indicated on the blister package. The course lasts 28 days, with one tablet taken daily. A new blister should start the day after the previous one.
Withdrawal bleeding usually begins on the second day after switching to hormone-free last-line tablets and may continue until new-pack tablets are taken. It is important to start a new blister on the same day of the week to keep bleeding that occurs on about the same dates each month regular.
- Nosology ethinylestradiol (ICD codes)
- L70.0
- Acne vulgaris [acne vulgaris]
- N94.3
- Premenstrual tension syndrome
- Z30.0
- General advice and advice on contraception
